Loading...

We've got a brand new version of Simply Wall St! Try it out

Foresee Pharmaceuticals

GTSM:6576
Snowflake Description

Exceptional growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6576
GTSM
NT$6B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Foresee Pharmaceuticals Co., Ltd., a clinical-stage biopharmaceutical company, engages in the development and commercialization of drugs in Taiwan and internationally. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
6576 Share Price and Events
7 Day Returns
4.5%
GTSM:6576
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
10.5%
GTSM:6576
16%
TW Pharmaceuticals
17.7%
TW Market
6576 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Foresee Pharmaceuticals (6576) 4.5% 4% -11.5% 10.5% -14.3% -
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 6576 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 6576 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6576
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Foresee Pharmaceuticals's competitors could be found in our database.

Value

 Is Foresee Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Foresee Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Foresee Pharmaceuticals.

GTSM:6576 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:6576
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (0.24%))
0.791
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for GTSM:6576 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Foresee Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:6576 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 7.5%)
2020 -308.00 Analyst x1 -286.52
2021 837.00 Analyst x1 724.31
2022 1,467.77 Est @ 75.36% 1,181.56
2023 2,254.06 Est @ 53.57% 1,687.97
2024 3,117.80 Est @ 38.32% 2,171.93
2025 3,979.62 Est @ 27.64% 2,578.93
2026 4,782.25 Est @ 20.17% 2,882.90
2027 5,496.58 Est @ 14.94% 3,082.40
2028 6,116.31 Est @ 11.27% 3,190.70
2029 6,649.13 Est @ 8.71% 3,226.72
Present value of next 10 years cash flows NT$20,440.00
GTSM:6576 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$6,649.13 × (1 + 2.73%) ÷ (7.5% – 2.73%)
NT$143,260.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$143,260.22 ÷ (1 + 7.5%)10
NT$69,521.92
GTSM:6576 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$20,440.00 + NT$69,521.92
NT$89,961.92
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$89,961.92 / 100.25
NT$897.4
GTSM:6576 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$897.40
Current discount Discount to share price of NT$63.00
= -1 x (NT$63.00 - NT$897.40) / NT$897.40
93%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Foresee Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is NT$63 vs Future cash flow value of NT$897.4
Current Discount Checks
For Foresee Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Foresee Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Foresee Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Foresee Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Foresee Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6576 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$-6.12
GTSM:6576 Share Price ** GTSM (2019-11-18) in TWD NT$63
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Foresee Pharmaceuticals.

GTSM:6576 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6576 Share Price ÷ EPS (both in TWD)

= 63 ÷ -6.12

-10.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Foresee Pharmaceuticals is loss making, we can't compare its value to the TW Pharmaceuticals industry average.
  • Foresee Pharmaceuticals is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does Foresee Pharmaceuticals's expected growth come at a high price?
Raw Data
GTSM:6576 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
105.1%per year
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Foresee Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Foresee Pharmaceuticals's assets?
Raw Data
GTSM:6576 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$9.82
GTSM:6576 Share Price * GTSM (2019-11-18) in TWD NT$63
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:6576 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6576 Share Price ÷ Book Value per Share (both in TWD)

= 63 ÷ 9.82

6.41x

* Primary Listing of Foresee Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Foresee Pharmaceuticals is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Foresee Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Foresee Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Foresee Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
105.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Foresee Pharmaceuticals expected to grow at an attractive rate?
  • Foresee Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Foresee Pharmaceuticals's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Foresee Pharmaceuticals's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6576 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6576 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 105.1%
GTSM:6576 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 126.7%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6576 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6576 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 1,715 863 834 1
2020-12-31 402 -283 -308 1
2019-12-31 68 3,139 -696 1
2019-11-18
GTSM:6576 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 68 -435 -568
2019-06-30 76 -438 -511
2019-03-31 83 -359 -489
2018-12-31 26 -462 -552
2018-09-30 33 -489 -471
2018-06-30 32 -480 -456
2018-03-31 32 -439 -398
2017-12-31 24 -483 -443
2017-09-30 17 -437 -456
2017-06-30 9 -398 -439
2017-03-31 3 -351 -400
2016-12-31 -263 -309

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Foresee Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Foresee Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6576 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Foresee Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6576 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 8.32 8.32 8.32 1.00
2020-12-31 -3.07 -3.07 -3.07 1.00
2019-12-31 -7.10 -7.10 -7.10 1.00
2019-11-18
GTSM:6576 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 -6.12
2019-06-30 -5.68
2019-03-31 -5.67
2018-12-31 -6.55
2018-09-30 -5.73
2018-06-30 -5.70
2018-03-31 -4.99
2017-12-31 -5.67
2017-09-30 -5.98
2017-06-30 -5.91
2017-03-31 -5.55
2016-12-31 -4.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Foresee Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Foresee Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Foresee Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Foresee Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Foresee Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Foresee Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Foresee Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Foresee Pharmaceuticals's 1-year growth to the TW Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Foresee Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Foresee Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6576 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 67.62 -568.40 107.06 502.82
2019-06-30 75.88 -510.65 115.47 454.76
2019-03-31 83.01 -489.21 115.21 438.12
2018-12-31 26.04 -551.52 115.15 441.93
2018-09-30 33.04 -471.08 115.06 369.83
2018-06-30 32.06 -455.93 111.63 359.54
2018-03-31 31.83 -398.50 104.18 313.21
2017-12-31 23.73 -443.49 99.35 358.55
2017-09-30 16.73 -456.17 93.74 375.62
2017-06-30 9.44 -439.43 84.83 360.42
2017-03-31 2.53 -400.33 78.66 323.90
2016-12-31 -308.55 74.37 236.43
2016-09-30 -286.34 69.18 214.82
2016-06-30 -272.48 58.93 214.56
2016-03-31 -301.64 46.64 256.38
2015-12-31 -330.80 34.34 298.20
2015-09-30 -254.09 22.72 232.88
2015-06-30 -177.37 11.10 167.55
2015-03-31 -92.51 6.48 86.72
2014-12-31 -7.66 1.86 5.89
2013-12-31 -0.66 0.44 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Foresee Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Foresee Pharmaceuticals has efficiently used its assets last year compared to the TW Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Foresee Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Foresee Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Foresee Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Foresee Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Foresee Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Foresee Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Foresee Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Foresee Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Foresee Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Foresee Pharmaceuticals Company Filings, last reported 1 month ago.

GTSM:6576 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 983.79 0.00 716.10
2019-06-30 1,157.72 0.00 797.46
2019-03-31 465.18 0.00 102.55
2018-12-31 498.62 0.00 214.33
2018-09-30 665.07 0.00 409.20
2018-06-30 786.58 0.00 586.83
2018-03-31 503.85 0.00 320.51
2017-12-31 603.66 0.00 453.21
2017-09-30 690.86 0.00 577.53
2017-06-30 796.53 0.00 727.21
2017-03-31 539.41 0.00 508.59
2016-12-31 539.41 0.00 508.59
2016-09-30
2016-06-30 725.17 0.00 668.36
2016-03-31 725.17 0.00 668.36
2015-12-31 345.18 0.00 307.33
2015-09-30 345.18 0.00 307.33
2015-06-30 496.32 39.78 487.07
2015-03-31 496.32 39.78 487.07
2014-12-31 42.36 158.64 237.79
2013-12-31 16.37 0.00 19.24
  • Foresee Pharmaceuticals has no debt.
  • Foresee Pharmaceuticals has no debt compared to 5 years ago when it was 331.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Foresee Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.
  • Unable to confirm if Foresee Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Foresee Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Foresee Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Foresee Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Foresee Pharmaceuticals dividends.
If you bought NT$2,000 of Foresee Pharmaceuticals shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Foresee Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Foresee Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6576 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6576 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Foresee Pharmaceuticals has not reported any payouts.
  • Unable to verify if Foresee Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Foresee Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Foresee Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Foresee Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Foresee Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Foresee Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Foresee Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lawrence Gan
TENURE AS CEO 2.3 years
CEO Bio

Dr. Lawrence Gan has been the Chief Executive Officer of Foresee Pharmaceuticals Co., Ltd. since August 1, 2017 and serves as its President. Dr. Gan leads Foresee's global strategy including portfolio planning, technology and platform research, preclinical and clinical development, commercialization, M&A and capital market activities. Dr. Gan has 30-year strategic and operational experience in the pharmaceutical industry, deep scientific expertise in drug discovery and development in multiple therapeutic areas and a broad network of key relationships within the biotech and pharma industry, academia and government agencies. Before joining Foresee, Dr. Gan was President and Chief Executive Officer of the Development Center for Biotechnology (DCB) in Taipei, Taiwan. He transformed DCB, a non-profit agency, to function as an energetic pharma company and actively promoted biotech industry in Taiwan. Prior to returning to Taiwan in 2015, he served as Senior Director at Biogen, Inc., Director of Drug Discovery at Boehringer-Ingelheim, Senior Director at Millennium Pharmaceuticals, Inc., Director at the DuPont Merck Pharmaceuticals Co., and Principal Investigator at GSK. Dr. Gan participated in 5 NDA/BLA registrations and over 25 IND filings, as well as issued over eighty publications. Dr. Gan received his Ph.D. degree in Bioorganic Chemistry from Tulane University and conducted postdoctoral studies at M.I.T.

CEO Compensation
  • Insufficient data for Lawrence to compare compensation growth.
  • Insufficient data for Lawrence to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the Foresee Pharmaceuticals management team in years:

2.5
Average Tenure
  • The tenure for the Foresee Pharmaceuticals management team is about average.
Management Team

Ben Chien

TITLE
Chairman & Founder

Lawrence Gan

TITLE
CEO & President
TENURE
2.3 yrs

Yuhua Li

TITLE
Co-founder & VP of RD Pipeline

Max Chan

TITLE
Chief Financial Officer
AGE
52
TENURE
0.8 yrs

Yang Wen Jin

TITLE
Chief Scientific Officer
TENURE
4.2 yrs

Digger Chen

TITLE
General Counsel & VP
TENURE
2.4 yrs

John Mao

TITLE
Senior VP & Head of Development
TENURE
4.3 yrs

Yisheng Lee

TITLE
Chief Medical Officer & Representative Director

David Lau

TITLE
Senior Vice President of NCE Preclinical & Clinical Development
TENURE
2.6 yrs

Patricia Chou

TITLE
Consultant
AGE
51
Board of Directors Tenure

Average tenure of the Foresee Pharmaceuticals board of directors in years:

4.3
Average Tenure
  • The tenure for the Foresee Pharmaceuticals board of directors is about average.
Board of Directors

Yisheng Lee

TITLE
Chief Medical Officer & Representative Director
TENURE
6.8 yrs

Fu-Shiow Yin

TITLE
Independent Director
TENURE
3.7 yrs

Ben Chien

TITLE
Chairman & Founder

George Lee

TITLE
Director
TENURE
4.3 yrs

Vincent Yen

TITLE
Representative Director
TENURE
6.8 yrs

Sonia Wu

TITLE
Representative Director
TENURE
4.3 yrs

Jeff Wang

TITLE
Director
TENURE
3.7 yrs

Hank Lai

TITLE
Independent Director
TENURE
1.4 yrs

Frank Lee

TITLE
Independent Director
TENURE
3.7 yrs

Luo Ming Ling

TITLE
Supervisor
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Foresee Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Foresee Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Foresee Pharmaceuticals Co., Ltd., a clinical-stage biopharmaceutical company, engages in the development and commercialization of drugs in Taiwan and internationally. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat substance abuse and pain relief; and FP-002 for the treatment of acromegaly and carcinoid tumors, as well as FP-008 for the treatment of diabetic retinopathy, which are products in research stage. Its new chemical entity pipeline products consists of FP-020 to treat alport syndrome; FP-025, a selective oral MMP-12 inhibitor, which is in Phase II clinical trial for inflammatory and fibrotic diseases; and FP-045, an oral molecule agonist of aldehyde dehydrogenase 2 that completed Phase I clinical study for the treatment of acute myocardial infarction, stroke, peripheral arterial disease, radiation dermatitis, Parkinson’s disease, diabetes, cancer prevention, etc. The company's strategic partners include Pierre Fabre Medicament Production and ScinoPharm. Foresee Pharmaceuticals Co., Ltd. is headquartered in Taipei, Taiwan.

Details
Name: Foresee Pharmaceuticals Co., Ltd.
6576
Exchange: GTSM
Founded:
NT$6,315,608,250
100,247,750
Website: http://www.foreseepharma.com
Address: Foresee Pharmaceuticals Co., Ltd.
No. 19-3, Sanchong Road,
9th Floor-2,
Taipei,
115,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6576 Common Stock Taipei Exchange TW TWD 12. Apr 2016
Number of employees
Current staff
Staff numbers
0
Foresee Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:26
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/16
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.